With reference to the subject ‘Glenmark Pharmaceuticals to Present New Analysis of Pooled Data on Ryaltris, an Investigational Product for the Treatment of Seasonal Allergic Rhinitis, at the AAAAI 2019 Annual Meeting’, Glenmark Pharmaceuticals has informed about submission of media release which is self explanatory.
The above information is a part of company’s filings submitted to BSE.